[1] JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[2] YANAGIDA O, KANAI Y, CHAIROUNGDUA A, et al. Human L-type amino acid transporter 1(LAT1): characterization of function and expression in tumor cell lines[J]. Biochim Biophys Acta, 2001, 1514(2): 291-302.
[3] ROTTENBERG S, NYGREN A O, PAJIC M, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer[J]. Proceed Nat Acad Sci USA, 2007, 104(29): 12117-12122.
[4] TROCK B J, LEONESSA F, CLARKE R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance[J]. J Nat Cancer Inst, 1997, 89(13): 917-931.
[5] LIU X, SONG S, SHI C. Clinical significance of expression of multidrug resistance gene in breast cancer tissue[J].Natl Med J China(中华医学杂志), 1997, 77(7): 488-490.
[6] O'BRIEN M M, LACAYO N J, LUM B L, et al. Phase I study of valspodar(PSC-833)with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group[J]. Pediatr Blood Cancer,2010, 54(5): 694-702.
[7] BENDERRA Z, FAUSSAT A M, SAYADA L, et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias[J]. Clin Cancer Res, 2004, 10(23): 7896-7902.
[8] DIESTRA J E, SCHEFFER G L, CATALA I, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material[J]. J Pathol, 2002, 198(2): 213-219.
[9] CHATURVEDI P, TULSYAN S, AGARWAL G, et al. Influence of ABCB1 genetic variants in breast cancer treatment outcomes[J]. Cancer Epidemiol, 2013, 37(5): 754-761.
[10] LEVY P, GLIGOROV J, ANTOINE M, et al. Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients[J]. Breast Cancer Res Treat, 2013, 139(2): 421-428.
[11] RODRIGUES F F, SANTOS R E, MELO M B, et al. Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer[J]. Genet Mol Res, 2008, 7(1): 177-183.
[12] TSAI S M, LIN C Y, WU S H, et al. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms[J]. Clin Chim Acta, 2009, 404(2): 160-165.
[13] TULSYAN S, CHATURVEDI P, SINGH A K, et al. Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach[J]. Gene, 2014, 543(1): 69-75.
[14] ZHANG B L, SUN T, ZHANG B N, et al. Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer[J]. Chin Med J(中华医学杂志),2011, 124(2): 199-204.
[15] CHANG H, RHA S Y, JEUNG H C, et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients[J]. ESMO, 2009, 20(2): 272-277.
[16] KIM H J, IM S A, KEAM B, et al. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy[J]. Cancer Sci,2015, 106(1): 86-93.
[17] SANDUSKY G E, MINTZE K S, PRATT S E, et al. Expression of multidrug resistance-associated protein 2(MRP2)in normal human tissues and carcinomas using tissue microarrays[J]. Histopathology, 2002, 41(1): 65-74.
[18] HENNESS S, DAVEY M W, HARVIE R M, et al. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase Ⅱ alpha expression[J]. Int J Rad Oncol Biol Phys, 2002, 54(3): 895-902.
[19] ALLIKMETS R, GERRARD B, HUTCHINSON A, et al. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database[J]. Hum Mol Gen, 1996, 5(10): 1649-1655.
[20] DEAN M, HAMON Y, CHIMINI G. The human ATP-binding cassette(ABC)transporter superfamily[J]. J Lipid Res, 2001, 42(7): 1007-1017.
[21] DOYLE L A, YANG W, ABRUZZO L V, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells[J]. Proc Nat Acad Sci USA, 1998, 95(26):15665-15670.
[22] ROSS D D, YANG W, ABRUZZO L V, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines[J]. J Nat Cancer Inst, 1999, 91(5): 429-433.
[23] FETSCH P A, ABATI A, LITMAN T, et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues[J]. Cancer Lett, 2006, 235(1): 84-92.
[24] HO M M, HOGGE D E, LING V. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia[J]. Exp Hematol, 2008, 36(4): 433-442.
[25] YOH K, ISHII G, YOKOSE T, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer[J]. Clin Cancer Res, 2004, 10(5): 1691-1697.
[26] MASTROBERARDINO L, SPINDLER B, PFEIFFER R, et al. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family[J]. Nature, 1998, 395(6699): 288-291.
[27] KANAI Y, SEGAWA H, MIYAMOTO K, et al. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen(CD98)[J]. J Biol Chem, 1998, 273(37): 23629-23632.
[28] KAIRA K, ORIUCHI N, IMAI H, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage Ⅰ-Ⅲ nonsmall cell lung cancer[J]. Br J Cancer, 2008, 98(4): 742-748.
[29] KAIRA K, ORIUCHI N, IMAI H, et al. Expression of L-type amino acid transporter 1(LAT1)in neuroendocrine tumors of the lung[J]. Pathol Res Prac, 2008, 204(8): 553-561.
[30] KAIRA K, ORIUCHI N, TAKAHASHI T, et al. L-type amino acid transporter 1(LAT1)expression in malignant pleural mesothelioma[J]. Anticancer Res, 2011, 31(12): 407540-407582.
[31] KAIRA K, ORIUCHI N, IMAI H, et al. L-type amino acid transporter 1(LAT1)is frequently expressed in thymic carcinomas but is absent in thymomas[J]. J Surg Oncol, 2009, 99(7): 433-438.
[32] KOBAYASHI K, OHNISHI A, PROMSUK J, et al. Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells[J]. Neurosurgery, 2008, 62(2): 493-504.
[33] TOYODA M, KAIRA K, OHSHIMA Y, et al. Prognostic significance of amino-acid transporter expression(LAT1, ASCT2, and xCT)in surgically resected tongue cancer[J]. Br J Cancer, 2014, 110(10): 2506-2513.
[34] KAIRA K, SUNOSE Y, ARAKAWA K, et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer[J]. Br J Cancer, 2012, 107(4): 632-638.
[35] KAIRA K, TOYODA M, SHINO M, et al. Clinicopathological significance of L-type amino acid transporter 1(LAT1)expression in patients with adenoid cystic carcinoma[J]. Pathol Oncol Res, 2013, 19(4): 649-656.
[36] SAKATA T, FERDOUS G, TSURUTA T, et al. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer[J]. Pathol Int, 2009, 59(1): 7-18.
[37] RING B Z, SEITZ R S, BECK R, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer[J]. J Clin Oncol, 2006, 24(19): 3039-3047.
[38] BARTLETT J M, THOMAS J, ROSS D T, et al. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy[J]. Breast Cancer Res, 2010, 12(4): R47.
[39] KAIRA K, ORIUCHI N, TAKAHASHI T, et al. LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer[J]. Am J Transl Res, 2011, 3(5): 468-478.
[40] ASANO S, KAMEYAMA M, OURA A, et al. L-type amino acid transporter-1 expressed in human astrocytomas[J]. Biol Pharm Bull, 2007, 30(3): 415-422.
[41] SHIMIZU K, KAIRA K, TOMIZAWA Y, et al. ASC Amino-acid transporter 2(ASCT2)as a novel prognostic marker in non-small cell lung cancer[J]. Br J Cancer, 2014, 110(8): 2030-2039.
[42] FUCHS B C, BODE B P. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? [J]. Seminars Cancer Biol, 2005, 15(4): 254-266.
[43] KIM S G, KIM H H, KIM H K, et al. Differential expression and functional characterization of system L-amino acid transporters in human normal osteoblast cells and osteogenic sarcoma cells[J]. Anticancer Res, 2006, 26(3a): 1989-1996.
[44] RAJAN D P, KEKUDA R, HUANG W, et al. Cloning and functional characterization of a Na⁺-independent, broad-specific neutral amino acid transporter from mammalian intestine[J]. Biochim Biophys Acta, 2000, 1463(1): 6-14.
[45] YAZAWA T, SHIMIZU K, KAIRA K, et al. Clinical significance of coexpression of L-type amino acid transporter 1(LAT1)and ASC amino acid transporter 2(ASCT2)in lung adenocarcinoma[J]. Am J Transl Res, 2015, 7(6): 1126-1139.
[46] ZHAO Y, WANG L, PAN J. The role of L-type amino acid transporter 1 in human tumors[J]. Intract Rare Dis Res, 2015, 4(4): 165-169.
[47] ABE T, UNNO M, ONOGAWA T, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers[J]. Gastroenterology, 2001, 120(7): 1689-1699.
[48] MUTO M, ONOGAWA T, SUZUKI T, et al. Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma[J]. Cancer Sci, 2007, 98(10): 1570-1576.
[49] CHEN W L, WANG Y Y, ZHAO A, et al. Enhanced fructose utilization mediated by slc2a5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential[J]. Cancer Cell, 2016, 30(5): 779-791.
[50] YU M, YONGZHI H, CHEN S, et al. The prognostic value of GLUT1 in cancers: a systematic review and Meta-analysis[J]. Oncotarget, 2017,8(26):43356-43367.
[51] BURGER H, ZOUMARO-DJAYOON A, BOERSMA A W, et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2(hSLC22A2)[J]. Br J Pharmacol, 2010, 159(4): 898-908.
[52] TANIHARA Y, MASUDA S, KATSURA T, et al. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2[J]. Biochem Pharmacol, 2009, 78(9): 1263-1271.
[53] YOKOO S, YONEZAWA A, MASUDA S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity[J]. Biochem Pharmacol, 2007, 74(3): 477-487.
[54] FILIPSKI K K, MATHIJSSEN R H, MIKKELSEN T S, et al. Contribution of organic cation transporter 2(OCT2)to cisplatin-induced nephrotoxicity[J]. Clin Pharmacol Ther,2009, 86(4): 396-402.
[55] IWATA K, AIZAWA K, KAMITSU S,et al. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events[J]. Clin Exp Nephrol, 2012, 16(6): 843-851.
[56] KATSUDA H, YAMASHITA M, KATSURA H, et al. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity[J]. Biol Pharm Bull, 2010, 33(11): 1867-1871.
[57] SPROWL J A, VAN DOORN L, HU S, et al. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance[J]. Clin Pharmacol Ther, 2013, 94(5): 585-592.
[58] KLEIN J, BENTUR Y, CHEUNG D, et al. Renal handling of cisplatin: interactions with organic anions and cations in the dog[J]. Clin Invest Med, 1991, 14(5): 388-394.
[59] CIARIMBOLI G, DEUSTER D, KNIEF A, et al. Organic cation transporter 2 mediates cisplatin-induced oto-and nephrotoxicity and is a target for protective interventions[J]. Am J Pathol, 2010, 176(3): 1169-1180.
[60] SPROWL J A, CIARIMBOLI G, LANCASTER C S, et al. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2[J]. Proc Nat Acad Sci USA, 2013, 110(27): 11199-11204.
[61] LIU Y, ZHENG X, YU Q, et al. Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin[J]. Sci Transl Med, 2016, 8(348): 348ra97.
[62] SOWERS R, WENZEL B D, RICHARDSON C, et al. Impairment of methotrexate transport is common in osteosarcoma tumor samples[J]. Sarcoma, 2011,2011:834170.
[63] FAGANEL KOTNIK B, DOLZAN V, GRABNAR I, et al. Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia[J]. Leuk Lymphoma, 2010, 51(4): 724-726.
[64] CHIUSOLO P, GIAMMARCO S, BELLESI S, et al. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue[J]. Cancer Chemother Pharmacol, 2012, 69(3): 691-696.
[65] SWEET D H, CHAN L M, WALDEN R, et al. Organic anion transporter 3(Slc22a8)is a dicarboxylate exchanger indirectly coupled to the Na⁺ gradient[J]. Am J Physiol Ren Physiol, 2003, 284(4):763-769.
[66] CLARKE M L, MACKEY J R, BALDWIN S A, et al. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs[J]. Cancer Treat Res, 2002, 112: 27-47.
[67] GALMARINI C M, THOMAS X, CALVO F, et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia[J]. Br J Haematol, 2002, 117(4):860-868.
[68] PARMAR S, SEERINGER A, DENICH D, et al. Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells[J]. Pharmacogenomics, 2011, 12(4): 503-514.
[69] ISHIMOTO O, SUGAWARA S, INOUE A, et al. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer[J]. J Thora Oncol, 2006, 1(9): 979-983.
[70] DE GRAAN A J, LANCASTER C S, OBAIDAT A, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel[J].Clin Cancer Res, 2012, 18(16): 4433-4440.
[71] SVOBODA M, WLCEK K, TAFERNER B, et al. Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport[J]. Biomed Pharmacol, 2011, 65(6): 417-426.
[72] VAN DE STEEG E, STRANECKY V, HARTMANNOVA H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver[J]. J Clin Invest, 2012, 122(2): 519-528.